Recent positive Phase 3 results for the Merck-Moderna intismeran-Keytruda combination in resected melanoma have reinforced their decade-long 50/50 partnership on personalized mRNA cancer therapies, driving share gains for both without prompting a full merger. Merck has pursued other oncology and life-sciences deals, such as the Terns Pharmaceuticals acquisition, while facing Keytruda patent pressures that could favor deeper integration—but no regulatory filings, board approvals, or formal talks have emerged by mid-September 2026. High valuations around $86 billion, manufacturing scale challenges for individualized therapies, and limited calendar time reduce the likelihood of an announced transaction this year, supporting the 86% market-implied probability of no deal.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้วMerck & Moderna merger/acquisition announced in 2026?
Merck & Moderna merger/acquisition announced in 2026?
24% โอกาส
ใหม่
ใหม่
Dec 31, 2026
24% โอกาส
ใหม่
ใหม่
Dec 31, 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Recent positive Phase 3 results for the Merck-Moderna intismeran-Keytruda combination in resected melanoma have reinforced their decade-long 50/50 partnership on personalized mRNA cancer therapies, driving share gains for both without prompting a full merger. Merck has pursued other oncology and life-sciences deals, such as the Terns Pharmaceuticals acquisition, while facing Keytruda patent pressures that could favor deeper integration—but no regulatory filings, board approvals, or formal talks have emerged by mid-September 2026. High valuations around $86 billion, manufacturing scale challenges for individualized therapies, and limited calendar time reduce the likelihood of an announced transaction this year, supporting the 86% market-implied probability of no deal.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
ตลาดเปิดเมื่อ: Aug 19, 2026, 3:58 PM ET
ปริมาณการซื้อขาย
$458วันสิ้นสุด
Jan 1, 2027ตลาดเปิดเมื่อ
Aug 19, 2026, 3:58 PM ETผู้ตัดสินผล
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Recent positive Phase 3 results for the Merck-Moderna intismeran-Keytruda combination in resected melanoma have reinforced their decade-long 50/50 partnership on personalized mRNA cancer therapies, driving share gains for both without prompting a full merger. Merck has pursued other oncology and life-sciences deals, such as the Terns Pharmaceuticals acquisition, while facing Keytruda patent pressures that could favor deeper integration—but no regulatory filings, board approvals, or formal talks have emerged by mid-September 2026. High valuations around $86 billion, manufacturing scale challenges for individualized therapies, and limited calendar time reduce the likelihood of an announced transaction this year, supporting the 86% market-implied probability of no deal.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
ปริมาณการซื้อขาย
$458วันสิ้นสุด
Jan 1, 2027ตลาดเปิดเมื่อ
Aug 19, 2026, 3:58 PM ETผู้ตัดสินผล
0x65070BE91...Recent positive Phase 3 results for the Merck-Moderna intismeran-Keytruda combination in resected melanoma have reinforced their decade-long 50/50 partnership on personalized mRNA cancer therapies, driving share gains for both without prompting a full merger. Merck has pursued other oncology and life-sciences deals, such as the Terns Pharmaceuticals acquisition, while facing Keytruda patent pressures that could favor deeper integration—but no regulatory filings, board approvals, or formal talks have emerged by mid-September 2026. High valuations around $86 billion, manufacturing scale challenges for individualized therapies, and limited calendar time reduce the likelihood of an announced transaction this year, supporting the 86% market-implied probability of no deal.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย